WO1999017774A1 - Product and method for the treatment of hyperlipidemia - Google Patents
Product and method for the treatment of hyperlipidemia Download PDFInfo
- Publication number
- WO1999017774A1 WO1999017774A1 PCT/IB1998/001489 IB9801489W WO9917774A1 WO 1999017774 A1 WO1999017774 A1 WO 1999017774A1 IB 9801489 W IB9801489 W IB 9801489W WO 9917774 A1 WO9917774 A1 WO 9917774A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- niacin
- microspheres
- product
- hmg
- reductase inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002273298A CA2273298C (en) | 1997-10-07 | 1998-07-20 | Product and method for the treatment of hyperlipidemia |
AU89955/98A AU8995598A (en) | 1997-10-07 | 1998-07-20 | Product and method for the treatment of hyperlipidemia |
EP98941662A EP0969838B2 (en) | 1997-10-07 | 1998-07-20 | Controlled release compositions for the treatment of hyperlipidemia |
AT98941662T ATE283050T1 (en) | 1997-10-07 | 1998-07-20 | DELAYED RELEASE COMPOSITIONS FOR THE TREATMENT OF HYPERLIPIDEMIA |
DE69827777T DE69827777T9 (en) | 1997-10-07 | 1998-07-20 | Delayed-release compositions for the treatment of hyperlipidemia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE970731 | 1997-10-07 | ||
IE19970731A IE970731A1 (en) | 1997-10-07 | 1997-10-07 | Product and method for the treatment of hyperlipidemia |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999017774A1 true WO1999017774A1 (en) | 1999-04-15 |
Family
ID=11041609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1998/001489 WO1999017774A1 (en) | 1997-10-07 | 1998-07-20 | Product and method for the treatment of hyperlipidemia |
Country Status (9)
Country | Link |
---|---|
US (1) | US6090830A (en) |
EP (1) | EP0969838B2 (en) |
AT (1) | ATE283050T1 (en) |
AU (1) | AU8995598A (en) |
CA (1) | CA2273298C (en) |
DE (1) | DE69827777T9 (en) |
ES (1) | ES2235357T5 (en) |
IE (1) | IE970731A1 (en) |
WO (1) | WO1999017774A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008127893A1 (en) * | 2007-04-04 | 2008-10-23 | Hight H Thomas | Niacin-based pharmaceutical compositions |
WO2010010579A1 (en) * | 2008-07-19 | 2010-01-28 | Lupin Limited | Multiple unit dosage form of niacin |
CN101836987A (en) * | 2009-03-19 | 2010-09-22 | 西安万隆制药有限责任公司 | Compound niacin sustained release tablet |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US20040013613A1 (en) * | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
WO2000018374A1 (en) * | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
US20080213378A1 (en) * | 1998-10-01 | 2008-09-04 | Elan Pharma International, Ltd. | Nanoparticulate statin formulations and novel statin combinations |
US6428814B1 (en) * | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US20040141925A1 (en) * | 1998-11-12 | 2004-07-22 | Elan Pharma International Ltd. | Novel triamcinolone compositions |
US20040115134A1 (en) * | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
US7503493B2 (en) * | 1999-10-25 | 2009-03-17 | Silverbrook Research Pty Ltd | Method and system for digitizing freehand graphics with user-selected properties |
IL149422A0 (en) * | 1999-11-03 | 2002-11-10 | Smith Howard J & Ass Pty Ltd | Oral pharmaceutical compositions for liver therapy |
US20040156872A1 (en) * | 2000-05-18 | 2004-08-12 | Elan Pharma International Ltd. | Novel nimesulide compositions |
US7198795B2 (en) * | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
GB2380937A (en) * | 2001-10-18 | 2003-04-23 | David Ian Slovick | Method of dispensing a plurality of medical substances into capsules |
CA2475092C (en) * | 2002-02-04 | 2012-05-01 | Christian F. Wertz | Nanoparticulate compositions having lysozyme as a surface stabilizer |
US20040101566A1 (en) * | 2002-02-04 | 2004-05-27 | Elan Pharma International Limited | Novel benzoyl peroxide compositions |
AU2003222009A1 (en) * | 2002-03-18 | 2003-10-08 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative |
AU2003241478A1 (en) * | 2002-06-10 | 2003-12-22 | Elan Pharma International, Ltd. | Nanoparticulate sterol formulations and sterol combinations |
US20040258757A1 (en) * | 2002-07-16 | 2004-12-23 | Elan Pharma International, Ltd. | Liquid dosage compositions of stable nanoparticulate active agents |
JP5137228B2 (en) * | 2003-03-07 | 2013-02-06 | メルク・シャープ・アンド・ドーム・コーポレーション | Substituted azetidinone compounds, substituted azetidinone formulations and their use for the treatment of hypercholesterolemia |
DE602004018617D1 (en) | 2003-03-07 | 2009-02-05 | Schering Corp | SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF HYPERCHOLESTEROLMIA |
WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
ES2600577T3 (en) * | 2003-12-04 | 2017-02-09 | Bend Research, Inc. | Spray-solidification process using an extruder to prepare multiparticulate compositions of crystalline drugs |
CA2547774A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Method for making pharmaceutical multiparticulates |
JP2007513139A (en) * | 2003-12-04 | 2007-05-24 | ファイザー・プロダクツ・インク | Multiparticulate compositions with improved stability |
WO2005053640A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Azithromycin multiparticulate dosage forms by liquid-based processes |
WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
BRPI0416535A (en) * | 2003-12-04 | 2007-01-09 | Pfizer Prod Inc | spray freezing process employing an extruder to prepare multiparticulate azithromycin compositions preferably containing a poloxamer and a glyceride |
PL364348A1 (en) | 2004-01-12 | 2005-07-25 | PHARMENA Sp.z o.o. | Application of quaternary pyridine salts as vessel protection agent |
US20060211762A1 (en) * | 2004-12-06 | 2006-09-21 | Rongen Roelof M | Omega-3 fatty acids and dyslipidemic agent for lipid therapy |
AU2006329564A1 (en) | 2005-07-11 | 2007-07-05 | Pharmena North America Inc. | Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative |
CA2642195A1 (en) * | 2006-02-24 | 2007-09-07 | Teva Pharmaceutical Industries Ltd. | Fluvastatin sodium pharmaceutical compositions |
AU2007223787A1 (en) * | 2006-03-08 | 2007-09-13 | Pharmena North America Inc. | Combination therapy with non-selective COX inhibitors to prevent COX-related gastric injuries |
US20100178341A1 (en) * | 2008-06-11 | 2010-07-15 | Ranbaxy Laboratories Limited | BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR |
US20190111064A1 (en) * | 2017-10-18 | 2019-04-18 | Interstice Therapeutics, LLC | Statin + vitamin d combination drug and method of use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1255805A (en) * | 1967-12-16 | 1971-12-01 | Albert Ag Chem Werke | Improvements in delayed release pharmaceutical preparations and stabilisation of vitamins |
US5260305A (en) * | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2016467A1 (en) * | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
US5157025A (en) * | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
US5445769A (en) * | 1994-06-27 | 1995-08-29 | Fuisz Technologies Ltd. | Spinner head for flash flow processing |
US5458823A (en) * | 1994-10-28 | 1995-10-17 | Fuisz Technologies Ltd. | Method and apparatus for spinning feedstock material |
US5683720A (en) * | 1994-10-28 | 1997-11-04 | Fuisz Technologies Ltd. | Liquiflash particles and method of making same |
CA2298549C (en) † | 1997-07-31 | 2006-01-10 | Kos Pharmaceuticals, Inc. | Combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night |
-
1997
- 1997-10-07 IE IE19970731A patent/IE970731A1/en not_active IP Right Cessation
-
1998
- 1998-07-20 AT AT98941662T patent/ATE283050T1/en not_active IP Right Cessation
- 1998-07-20 US US09/119,225 patent/US6090830A/en not_active Expired - Lifetime
- 1998-07-20 EP EP98941662A patent/EP0969838B2/en not_active Expired - Lifetime
- 1998-07-20 AU AU89955/98A patent/AU8995598A/en not_active Abandoned
- 1998-07-20 WO PCT/IB1998/001489 patent/WO1999017774A1/en active IP Right Grant
- 1998-07-20 DE DE69827777T patent/DE69827777T9/en active Active
- 1998-07-20 ES ES98941662T patent/ES2235357T5/en not_active Expired - Lifetime
- 1998-07-20 CA CA002273298A patent/CA2273298C/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1255805A (en) * | 1967-12-16 | 1971-12-01 | Albert Ag Chem Werke | Improvements in delayed release pharmaceutical preparations and stabilisation of vitamins |
US5260305A (en) * | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008127893A1 (en) * | 2007-04-04 | 2008-10-23 | Hight H Thomas | Niacin-based pharmaceutical compositions |
WO2010010579A1 (en) * | 2008-07-19 | 2010-01-28 | Lupin Limited | Multiple unit dosage form of niacin |
CN101836987A (en) * | 2009-03-19 | 2010-09-22 | 西安万隆制药有限责任公司 | Compound niacin sustained release tablet |
CN101836987B (en) * | 2009-03-19 | 2013-03-27 | 西安万隆制药股份有限公司 | Compound niacin sustained release tablet |
Also Published As
Publication number | Publication date |
---|---|
US6090830A (en) | 2000-07-18 |
EP0969838B2 (en) | 2010-01-13 |
EP0969838A1 (en) | 2000-01-12 |
DE69827777T3 (en) | 2010-07-29 |
IE970731A1 (en) | 2000-10-04 |
CA2273298A1 (en) | 1999-04-15 |
DE69827777T9 (en) | 2010-11-11 |
ES2235357T3 (en) | 2005-07-01 |
EP0969838B1 (en) | 2004-11-24 |
DE69827777D1 (en) | 2004-12-30 |
ATE283050T1 (en) | 2004-12-15 |
DE69827777T2 (en) | 2005-12-22 |
AU8995598A (en) | 1999-04-27 |
CA2273298C (en) | 2008-04-08 |
ES2235357T5 (en) | 2010-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6090830A (en) | Controlled release compositions and methods for the treatment of hyperlipidemia | |
US8703202B2 (en) | Coated tablets | |
EP1361867B1 (en) | Fibrate-statin combinations with reduced fed-fasted effects | |
EP1322289B1 (en) | Spray drying process of compositions containing fenofibrate | |
EP2136792B1 (en) | Hot-melt micropellets | |
WO2002024193A1 (en) | Stabilised fibrate microparticles | |
US5965167A (en) | Dosage units | |
CA2484375C (en) | Oral dosage forms comprising fenofibrate | |
US8821936B2 (en) | Solid pharmaceutical formulation | |
MXPA04008137A (en) | Sustained release preparations and process for producing the same. | |
WO2004028506A1 (en) | Oral pharmaceutical compositions of fenofibrate having high bioavailability | |
WO2005051346A2 (en) | Compositions comprising organic compounds | |
NZ231954A (en) | Aqueous coating formulations for coating aspirin granules; aspirin tablets having zero order release kinetics | |
WO2007064083A1 (en) | Spray-dried granules and processes for the preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2273298 Country of ref document: CA |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998941662 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998941662 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998941662 Country of ref document: EP |